Platinum-based chemotherapy in metastatic triple-negative breast cancer: the Institut Curie experience
- 5 October 2010
- journal article
- research article
- Published by Elsevier BV in Annals Of Oncology
- Vol. 22 (4), 848-856
- https://doi.org/10.1093/annonc/mdq461
Abstract
Background: Although recent experimental data strongly suggest that platinum-based chemotherapy (PBCT) could improve the outcome of triple-negative breast cancer (TNBC), clinical data are lacking. Here, the authors reviewed clinical outcome in patients with metastatic TNBC treated with PBCT. Patients and methods: We conducted a retrospective analysis of all patients (N = 143) treated for metastatic breast cancer with PBCT between 2000 and 2008, at Institut Curie, Paris, France. Ninety-three of them (63.7%) had TNBC. One-hundred twenty patients received cisplatin (CDDP). The main combination used was CDDP–ifosfamide, in 101 patients (70.2%). Results: Median follow-up was 44 months. For the overall population (N = 143), median overall survival (OS) and median progression-free survival (PFS) were 11 and 5 months, respectively. Objective response rate was 33.3% in the TNBC group versus 22% in non-TNBC, P = 0.1. We observed no difference of OS, PFS and response duration. Other prognostic factors for poor OS were visceral metastasis sites (P < 0.001). One patient died from sepsis during aplasia, 15 had to switch from CDDP to carboplatin because of CDDP-related toxicity. Conclusions: Metastatic TNBC patients treated with PBCT tended to have a higher response rate, without a significant improvement of PFS or OS, compared with other subtypes. Toxicity was acceptable. Longer observation and further analysis are warranted.Keywords
This publication has 37 references indexed in Scilit:
- Gene-Expression Signatures in Breast CancerNew England Journal of Medicine, 2009
- Impact of Triple Negative Phenotype on Breast Cancer PrognosisThe Breast Journal, 2008
- Triple negative tumours: a critical reviewHistopathology, 2007
- Descriptive analysis of estrogen receptor (ER)‐negative, progesterone receptor (PR)‐negative, and HER2‐negative invasive breast cancer, the so‐called triple‐negative phenotypeCancer, 2007
- Prognostic markers in triple‐negative breast cancerCancer, 2006
- BRCA1 dysfunction in sporadic basal-like breast cancerOncogene, 2006
- Hallmarks of 'BRCAness' in sporadic cancersNature Reviews Cancer, 2004
- A Gene-Expression Signature as a Predictor of Survival in Breast CancerNew England Journal of Medicine, 2002
- Global cancer statistics in the year 2000The Lancet Oncology, 2001
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000